L-arginine Effects on Chronic Hypertension in Pregnancy

Effects of Oral L-arginine on Chronic Hypertension in Pregnancy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00974714

Enrollment

Registered

2009-09-10

Start date

2007-09-30

Completion date

2009-12-31

Last updated

2010-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension in Pregnancy

Keywords

chronic hypertension in pregnancy

Brief summary

The purpose of this study is to evaluate the effects of oral L-arginine administration on pregnant women at second trimester of gestation with chronic hypertension, respect with placebo.

Interventions

DRUGL-arginine

Oral L-arginine 2 g twice a day for 14 weeks

OTHERplacebo

oral placebo 2 g twice a day for 14 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Pregnant women between 18-20 weeks of gestation with chronic hypertension

Exclusion criteria

* Other maternal or fetal systemic disease

Design outcomes

Primary

Measure	Time frame
to evaluate blood pressure changes during oral L-arginine or placebo administration in pregnant women with chronic hypertension at second trimester of gestation	14 weeks

Secondary

Measure	Time frame
evaluate if is necessary to add a conventional therapy for hypertension, to evaluate pregnancy outcomes and eventual complications, to evaluate safety of oral L-arginine administration	14 weeks

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026